NCT02795858 2025-02-19
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
Dana-Farber Cancer Institute
National Cancer Institute, Naples
Shanghai Jiao Tong University School of Medicine
First Affiliated Hospital, Sun Yat-Sen University
University Hospital Freiburg